Carvykti (ciltacabtagene autoleucel)

pCPA File Number: 22363
Negotiation Status:
Active Negotiation
For the treatment of adult patients with multiple myeloma (MM) who have received at least three prior lines of therapy, including a proteasome inhibitor, an immunomodulatory agent, and an anti-CD38 antibody, and who are refractory to their last treatment.
Janssen Inc.
CADTH Project Number:
pCPA Engagement Letter Issued:
Negotiation Process Concluded:
Not Applicable